Luca Gilotti is a Partner and has been a member of Centerview Partners’ Healthcare practice since its inception. During his career, Mr. Gilotti has advised a diverse number of Pharma, Biotech and Healthcare Services clients across a broad range of strategic advisory assignments and transactions.

Mr. Gilotti’s recent assignments include advising Vifor on its $11.7bn sale to CSL; Mayne Pharma on its $475m sale of Metrics Contract Services to Catalent; Recipharm on its acquisitions of Arranta Bio and Vibalogics; Sanofi on its $1.9bn acquisition of Kadmon; Karo Pharma on its €290m acquisition of Sylphar; Reckitt on its $1.1bn acquisition of Biofreeze and sale of Scholl for £275m and E45 for £200m; MolMed on its €240m sale to AGC; Hikma Pharmaceuticals on its acquisitions of Boehringer Ingelheim’s Roxane Laboratories for $1.6bn and Bedford Laboratories for up to $300m, its acquisition of Baxter’s U.S. Multi-Source injectables business for $112m, and its acquisition of 94% of Promopharm for $153m; Aspen on the sale of its Global Infant Nutritionals business to Lactalis for $860m; Santhera on its acquisition from Idorsia of an option to purchase vamorolone for up to ~$480m and sale of idebenone rights in LHON to Chiesi for CHF 105m; Ares Life Sciences on its acquisitions of a stake in Euromedic, Greer Laboratories for $300m and Antigen Labs; and Biological E on the formation of a vaccines-focused Joint Venture with GlaxoSmithKline.

Prior to Centerview Partners, Mr. Gilotti worked in the Global Investment Banking team at Bank of America, and later Bank of America Merrill Lynch, advising clients across a range of products including M&A, DCM and ECM.

Mr. Gilotti holds a B.A. and M.A. in Philosophy, Politics and Economics from the University of Oxford. Mr. Gilotti is based in London.